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The National Institute for Clinical Excellence (NICE) was
established to improve the quality of health care in England and
Wales through the provision of guidance on the clinical and cost-
effectiveness of health interventions.
The treatment of cancer is one of the government’s priority areas
and a range of guidance products have been developed by the
Institute to support implementation of national cancer initiatives.
Out of a total of 56, 15 technology appraisals issued in the first 3
years of the Institute’s existence are related to the general area of
oncology, with another four in preparation. Two service guidance
documents on breast and urological cancer have been issued, with
six in progress. Clinical guidelines on lung cancer and familial breast
cancer have been commissioned and the Department of Health’s
referral guidance for patients with suspected cancer is being updated.
This paper describes how the Institute develops the clinical
guidelines component of its guidance portfolio.
THE ROLE OF THE INSTITUTE
NICE was established as a special Health Authority in April 1999. It
has four main aims:
(I) to speed up the uptake by the National Health Service (NHS)
of interventions that are both clinically and cost effective;
(II) to encourage more equitable access to healthcare (i.e. ‘reduce
the postcode lottery of care’);
(III) to provide better and more rational use of available resources
by focusing the provision of health care on the most cost-
effective interventions; and
(IV) to encourage the creation of new and innovative technologies.
The Institute achieves these aims by providing guidance to the
NHS on the effectiveness and cost-effectiveness of clinical
interventions. This task is achieved by appraising new and existing
technologies and developing disease-specific clinical guidelines. In
addition, the Institute has responsibility for the four national
confidential enquiries and more recently for assessing the safety
and efficacy of new interventional procedures (previously the
responsibility of SERNIP–Safety and Efficacy Register of New
Interventional Procedures) and advising on the safety of borderline
substances. The previous work of the Cancer Clinical Outcomes
Group on service guidance to support the implementation of the
Calman Hine report (see separate editorial) and the cancer referral
guidance are also now part of the NICE portfolio of guidance
(Table 1 shows the Institute’s products in the field of cancer care).
In its first 3 years, the Institute’s main output has been in the
technology appraisals programme and this has created consider-
able interest and some controversy, particularly in the area of
oncology. The explicit approach that the Institute has adopted in
reaching its decisions has highlighted difficult ethical issues that
need to be addressed in seeking to balance the desires of
individuals with population health requirements. Details of how
the Institute is responding to these challenges is documented
elsewhere (Littlejohns et al, 2003).
QUALITY ASSURANCE
Politicians have given strong messages about the need to improve
quality within the NHS and have developed a ‘quality improve-
ment’ model with education and support being key driving forces.
The various institutions involved in this developing quality
initiative, NICE, the Modernisation Agency (Cancer Services
Collaborative), the Commission for Health Improvement, the
National Clinical Governance Support Team, and more recently
the National Patient Safety Agency, have indicated that their role is
to support the NHS in addressing the daily challenges of delivering
high-quality health care. This is particularly important when
expectations and demand frequently exceed what is feasible within
current service configurations.
The Institute’s contribution was first outlined in the white papers,
entitled ‘The new NHS: modern and dependable’ and ‘A first class
service: quality in the new NHS’ (Department of Health, 1997,
1998). Standards for service configuration are established at a
national level through the creation of national service frameworks
(in the context of cancer services, the national plan) and clinical
standards are established through the guidance issued by NICE.
In this context, the Institute considers that a key role is to
provide guidance on controversial health issues where lack of
clarity has resulted in regional variation in the care provided by
the NHS. The guidance produced is expected to be incorporated
into local clinical governance mechanisms (including cancer
networks) via the use of local guidelines and protocols.
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NICE produces clinical guidelines (defined as systematically
developed statements to assist practitioner and patient decisions
about appropriate health care for specific clinical circumstances
that cover all aspects of patient care from prevention and self-care
through primary and secondary care to more specialised services
(Field and Lohr, 1990).
In the past, while there have been many professional groups and
organisations producing guidelines, these were of variable quality
and none addressed cost-effectiveness (Grilli et al, 2000). A
guideline development programme has been designed that is
evidence based, consultative, transparent and inclusive, and
adheres to internationally recognised standards of practice (The
AGREE Collaboration, 2003). Details of the process are described
in a series of manuals available at the following Internet address:
http://www.nice.org.uk/cat.asp?c¼22334. The principles under-
lying the Institute’s clinical guidelines are given in Table 2.
The main role of the Institute is to commission, coordinate and
quality assure the process. To achieve this, it relies on its
commissioning managers and the Guidelines Advisory Committee
(to be reconfigured as guideline review panels from 1st April
2003). The members provide external validation for the guidelines
by overseeing the development process, advising on the commis-
sioning of work and monitoring the quality of the guidelines.
These members have a range of backgrounds and knowledge,
including guideline expertise, clinical experience, patient/carer
involvement and health economics.
THE NATIONAL COLLABORATING CENTRES AND
THE SUPPORT UNITS
Six professionally led National Collaborating Centres (NCCs) have
been established. A seventh collaborating centre specialising in
cancer guidance has recently been commissioned. Each centre is a
multidisciplinary collaboration of professionals, user representa-
tives and technical experts.
They are expected to have access to a range of skills and abilities,
either via an academic unit or by employing appropriate staff.
These include clinical networks to support the proposed range of
activities, expertise in engaging with patients and patient groups
and methodological skills for guideline development. In addition
to the NCCs, the Institute has established two support units to
undertake guideline methodological research and assist patients to
participate actively in the guideline development process.
GUIDELINE TOPICS
The Department of Health for England and the Welsh Assembly
Government select topics for the Institute’s work programme.
Topics are selected on the basis of whether a guideline would:
  have significant health benefits (e.g. reduce illness, disability or
premature death);
  have a significant impact on NHS resources;
  complement one or more of the Institute’s technology
appraisals;
  link with key Government priorities for health; and
  help to resolve unacceptable variation in practice across
England and Wales.
GUIDELINE DEVELOPMENT PROCESSES
Each clinical guideline is developed in a process comprising seven
phases: initiation, scoping, elaboration of a work plan, develop-
ment, validation, publication and dissemination, review and
update.
Initiation
The Department of Health and the Welsh Assembly Government
formally refer the guidelines work programme to the Institute.
Once referred, notification of the programme is given through a
press release and via the Institute’s web site. A topic is allocated to
a National Collaborating Centre, which begins the scoping exercise
for the guidelines producing a provisional timetable for the work
programme, drawing up timelines and identifying potential
stakeholders for each guideline. A provisional timetable and
details of the work programme are posted on the Institute’s web
site.
For the purposes of the Institute’s clinical guideline develop-
ment, stakeholders are:
  the national patient and carer organisations that represent
people whose care is described in the guideline;
  the national organisations that represent the healthcare profes-
sionals who are directly providing the services described in the
guideline;
  the companies or manufacturers of the medicines or devices
used in the clinical area covered by the guideline and whose
interests are may be significantly affected by the guideline;
  a number of primary care organisations and acute trusts–these
organisations are invited to act as NHS stakeholders for a
particular guideline; and
  the Department of Health and Welsh Assembly Government.
Scoping
The scoping document is then drawn up. It describes the aspects of
care that the guideline will cover, the background epidemiology,
the population, the healthcare setting, and inclusions and
exclusions of interventions and treatments. This goes through a
period of external consultation following which the final scope is
posted on the Institute’s web site.
During the scoping phase, there is a meeting with all stakeholder
organisations. In addition, the Patient Involvement Unit arranges a
meeting for patient/carer stakeholder organisations to describe the
opportunities for them to contribute to guideline development
(including opportunities to nominate patient/carer representatives
to sit on the Guideline Development Group) and to discuss the
scope of the guideline and what this might mean to patients and
carers.
Elaboration of a work plan
Following agreement of the scope with the Collaborating Centre,
the Institute works with the NCC to prepare a detailed work plan.
This will follow a standard template and includes information on
costs, timelines, methodology and the proposed membership of the
Guideline development Group.
Development
The Collaborating Centre is responsible for the development of the
guideline through the establishment of the Guideline Development
Group, with membership capable of considering and interpreting
the evidence presented to it and formulating recommendations on
appropriate clinical practice.
The membership of the Group should reflect the range of clinical
disciplines involved in providing care and should include patient/
carer representatives. The facilitator/chairman is selected by the
NCC, in agreement with the Institute.
The key stages in the development of the Institute’s guidelines
are described in detail in Chapter 3 of the Health Technology
Assessment monograph ‘How to Develop Cost-conscious Guide-
lines’ (Eccles and Mason, 2001). Also, a technical manual building
on the first 2 years’ experiences of the NCCs is being compiled. Key
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by the National Collaborating Centre, and highlight appropriate
data that will become available during the development phase.
The Institute’s guidelines are expected to address cost effective-
ness as well as clinical effectiveness. There are a number of
possible ways in which economic methods can be used in the
production of clinical guidelines, such as profiling, modelling,
cost–impact assessment, and using literature reviews of economic
analyses. The guideline development process incorporates a health
economist whose prime role is to argue for full discussion and
useful presentation of the value of treatment alternatives.
All commissioned guidelines are subject to a period of imple-
mentation planning with local health communities (geographical
clusters of one or more primary- and secondary-care providers in
England and Wales).
Validation
Three versions of the guideline are produced based on the
recommendations of the National Collaborating Centre (Table 3).
These go through a two-stage consultation process, which offers an
opportunity for wide consultation on the drafts. Within this
process, stakeholders comment on the draft guideline and the
developers respond to all received comments. Following this
consultation, the redrafted guideline, and all the comments and
responses are considered by a subgroup of the Guidelines Advisory
Committee. In response to their advice the final draft of the full
guideline, short-form guideline and patient version are prepared
by the Collaborating Centre. The Chair of the sub-group signs off
the final draft of the full guideline on behalf of the Guidelines
Advisory Committee and submits it to the Institute. Following
approval, the Institute signs off the final draft of the full guideline
and returns the final draft to the Collaborating Centre for
publication.
Publication and dissemination
The short version guideline and the patient version are published
by the Institute. Copies of the full version of the guideline are
available from the Collaborating Centre.
Review and update
When the Institute publishes the guideline, a date is given on
which the guidance will be reviewed. The length of time between
the issue of the guideline and the review date varies depending on
the anticipated rate of change in the evidence for the guideline.
CONCLUSIONS
This is an ambitious programme. The wide range of its portfolio
makes the Institute’s guidance programme among the largest in
the world. Its sustainability will depend on liaising with many
professional and patient organisations within the UK as well as
initiating international collaborations. The Institute is looking
forward to contributing to a European-wide approach to develop-
ing cancer guidelines (Philip et al, 2003). NICE’S responsibility for
providing guidance on cost-effectiveness as well as clinical
effectiveness will ensure that it will continue to be controversial
and to challenge the status quo.
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